Uppsala University Hospital
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1708-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- https://www.akademiska.se
Elicera's iTANK-Armed CAR T-Cell Therapy Shows Complete Response in Lymphoma Patients
• Elicera Therapeutics reports that two out of three patients in the first cohort of the CARMA study achieved complete metabolic response with ELC-301, an iTANK-armed CD20-targeting CAR T-cell therapy.
• The promising results were achieved despite using only one-tenth of the planned maximum dose in a challenging patient population, including one patient who had previously failed standard CD19 CAR T-cell therapy.
• The Phase I/IIa CARMA study has already progressed to its second cohort, where patients are receiving a dose three times higher than the initial cohort, with further data expected as the trial advances.
Sana Biotechnology Achieves Breakthrough in Type 1 Diabetes Treatment Without Immunosuppression
Sana Biotechnology has reported promising early trial results for type 1 diabetes treatment using allogeneic pancreatic islet cell transplantation without the need for immunosuppression. This groundbreaking development represents the first human evidence of successfully overcoming both allogeneic and autoimmune rejection in type 1 diabetes treatment.
Tenvie Therapeutics Launches with $200M for Neurodegeneration Drug R&D; Sana Biotechnology Achieves Landmark in Type 1 Diabetes Transplant
• Tenvie Therapeutics, backed by Arch Venture Partners and others, debuts with $200 million to develop drugs targeting neurodegenerative diseases.
• Sana Biotechnology's technology enables successful pancreatic islet cell transplant in a Type 1 diabetes patient without immunosuppression.
• Jasper Therapeutics shares mixed Phase 1b/2a data on briquilimab for chronic spontaneous urticaria, leading to a stock decline.
• Stoke Therapeutics finalizes plans for a Phase 3 trial of its experimental drug for Dravet syndrome, with data expected by 2027.
Sana Biotechnology's Breakthrough in Type 1 Diabetes Treatment
Sana Biotechnology's UP421 islet cell therapy shows promising results in a Type 1 diabetes patient, marking a significant step towards a scalable, curative treatment without the need for immunosuppression.
Sana Biotechnology's Hypoimmune Cell Therapy Shows Promise in Type 1 Diabetes
• Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression.
• The first-in-human study showed increased C-peptide levels, indicating insulin production, and sustained signals at the transplant site via MRI.
• TD Cowen upgraded Sana Biotechnology to Buy, noting the results meaningfully derisk type 1 diabetes and other applications of the Hypoimmune platform.
• The company's stock price surged following the release of the positive data, reflecting investor optimism about the potential of the new treatment.
Sana Biotechnology's HIP Technology Shows Promise in Type 1 Diabetes Islet Cell Transplant Study
• Sana Biotechnology's UP421 demonstrates survival and function of transplanted islet cells in a type 1 diabetes patient without immunosuppression.
• The first-in-human study shows HIP-engineered cells evade immune detection, producing insulin as indicated by increased C-peptide levels.
• MRI scans confirm graft survival 28 days post-transplantation, with no reported safety issues, suggesting potential for a curative T1D treatment.
• These results support the development of Sana's SC451, a stem cell-derived islet cell program, offering hope for scalable T1D therapies.
CAR-Enhancers Show Promise in Prolonging Remission in CAR T-Cell Therapy
• Researchers at Dana-Farber Cancer Institute have developed CAR-enhancers (CAR-E) to extend the effectiveness of CAR T-cell therapy.
• CAR-E aims to prevent relapse by maintaining the activity of CAR T-cells and promoting the formation of memory cells.
• The new CAR-E therapy is set to begin a phase I clinical trial focusing on safety, dosage, and treatment schedule post CAR T-cell infusion.
• CAR T-cell therapy, while effective for blood cancers, faces challenges with relapse due to T-cell exhaustion.
AlzeCure Pharma to Present Update on Phase II Neuropathic Pain Candidate ACD440
• AlzeCure Pharma will host a live event on October 23rd to discuss their Phase II candidate ACD440 for chronic neuropathic pain.
• The symposium will feature an overview of pain management by Dr. Rolf Karlsten and an update on ACD440 by CMO Märta Segerdahl.
• ACD440, a topical TRPV1 antagonist, showed positive proof-of-mechanism results, reducing pain induced by cold and heat by approximately 50% in trials.
• The event will cover AlzeCure's progress in developing non-opioid pain treatments and include a Q&A session with company executives.
© Copyright 2025. All Rights Reserved by MedPath